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Urinary incontinence can cause embarrassment and can impact on daily activities and quality of life. Generic health
related quality of life instruments, such as the EQ-5D, are designed to be applicable across a variety of disease areas.
However, it is sometimes claimed that they are not applicable to a certain disease area because they are missing a
domain which directly captures the impact of that particular disease. For example, none of the domains of the
EQ-5D relate directly to incontinence, although the impact of incontinence on quality of life may be expected to
be picked up indirectly through changes in domains such as usual activities or anxiety/depression. The objective of
this review was to examine the appropriateness of the EQ-5D in people with urinary incontinence by reviewing
published evidence relating to the psychometric performance of the EQ-5D. A systematic search was conducted to
identify studies reporting data that permitted assessment of the construct validity, responsiveness or reliability of
the EQ-5D in people with urinary incontinence. Included papers were those that reported EQ-5D alongside other
measures of health related quality of life or clinical measures in patients with urinary incontinence or in a broader
population where results were reported for a subgroup of patients with urinary incontinence. Data were extracted
and a narrative synthesis was undertaken. Seventeen papers were included in the review. In most of the tests
performed, EQ-5D was consistent with clinical or disease specific outcome measures. The EQ-5D demonstrated
validity in the majority of ‘known group’ comparisons, although statistical significance was not always reported.
Correlations between the EQ-5D and disease specific outcomes were statistically significant and in the expected
direction for most but not all of the disease specific instruments and clinical measures. For responsiveness, there
was general agreement between changes in EQ-5D and changes in clinical or disease specific measures. Evidence
on reliability was limited to one study. The EQ-5D was generally found to perform well on tests of construct
validity, responsiveness and reliability, in people with urinary incontinence although no definitive conclusion can be
made on its appropriateness based on these measures alone.
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Introduction
Urinary incontinence (UI) has been defined by the incon-
tinence society as “the complaint of any involuntary urinary
leakage” [1]. UI can cause embarrassment and can impact
on daily activities and quality of life [2,3]. It can lead to de-
pression, anxiety and can carry considerable health care
costs [4]. UI is often categorised as either stress, urge or
mixed. Stress incontinence is associated with effort, exer-
tion, sneezing or coughing, whilst urge incontinence is
when leakage is accompanied or immediately preceded by* Correspondence: s.davis@sheffield.ac.uk
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distribution, and reproduction in any mediumurgency. The term mixed incontinence is used when
features of both stress and urge incontinence are present.
Treatments which improve continence may have a
beneficial impact on the individual’s health related quality
of life (HRQoL). Reimbursement agencies are interested
in knowing the impact of treatment on HRQoL when
making decisions regarding whether a treatment should
be made available within their health care system. Often
these decisions are informed by cost-utility analyses in
which treatment benefits are expressed as a change in
quality adjusted life years (QALYs). QALYs are useful as
they facilitate comparisons of health benefits across differ-
ent interventions, patients and disease areas. In order to
calculate treatment benefit in terms of QALY gains, anntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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gle metric for HRQoL, where one represents a state of full
health and zero represents a state equivalent to death.
Negative values are possible as these represent states that
are considered to be worse than death. Whilst there are a
variety of generic and disease specific instruments avail-
able to measure HRQoL, only a few of these provide the
preference based measurement of health utility required
for cost-utility analyses.
One of the most widely used generic preference based
instruments is the EQ-5D. The EQ-5D is a generic instru-
ment intended to measure and value health outcomes
across a wide range of diseases and treatments. It is there-
fore described as a generic rather than a condition specific
instrument. It consists of two main components. First, a
classification or descriptive system that covers five health
domains: mobility, self-care, usual activities, pain/discom-
fort and anxiety/depression. The standard and most wide-
spread version of the EQ-5D has three levels: no problems,
some problems, severe problems. There are therefore 243
health states that can be described in what is generally
accepted as a simple approach to describing health. Second,
a single valuation (EQ-5D index or tariff) is provided for
each particular health state in the descriptive system. The
EQ-5D is the preferred instrument for measuring health
utilities in adults within the Technology Appraisals
Programme at the National Institute for Health and Clinical
Excellence (NICE) [5].
Whilst generic HRQoL instruments are designed to be
applicable across a variety of disease areas, it is some-
times claimed that they are not applicable to a certain
disease area because they are missing a domain which
directly captures the impact of that particular disease. In
the case of UI, the EQ-5D lacks any domain that directly
relates to continence, although the impact of incontinence
on HRQoL may be expected to be picked up indirectly
through changes in domains such as usual activities or
anxiety/depression. Evidence is therefore needed on the
appropriateness of the EQ-5D in this setting. Psychomet-
ric methods are often employed to inform assessment of
the appropriateness of an instrument for use within a par-
ticular population. The aim of this review was to examine
the appropriateness of the EQ-5D for measuring health
utility in people with UI by examining all published evi-
dence relating to the psychometric performance of the
EQ-5D.
Methods
Search strategy and data extraction
The search strategy combined free text terms aimed at
identifying papers reporting EQ-5D with free text and
controlled terms (MESH and MESH-like terms) for UI.
The following databases were searched in May 2010;
BIOSIS, CINAHL, Cochrane Library (comprising CDSR,CENTRAL, NHS EED), EMBASE, Euroqol website,
MEDLINE, PsychNFO, Web of Science. The search strat-
egy for MEDLINE is provided in the Additional file 1.
Included papers were those that reported EQ-5D along-
side other measures of HRQoL or clinical measures in
patients with UI or in a broader population where results
were reported for a subgroup of patients with UI. Papers
reporting valuations of clinical vignettes were excluded.
There were no restrictions relating to study design or
interventions. Relevant systematic reviews and economic
evaluations were ordered and their references checked for
additional papers reporting primary data. Only English
language studies were reviewed. Titles and abstracts were
sifted by two reviewers independently with discussion used
to resolve any inclusion / exclusion discrepancies. Full text
papers were sifted by a sole reviewer.
Data were extracted using a standardised set of forms.
Data extracted included study characteristics (country,
study design, type of incontinence and severity measures,
treatment where relevant), participant characteristics (num-
ber, age, gender, ethnicity), outcome measures and results
of psychometric tests.
Psychometric measures
When establishing the appropriateness of a HRQoL instru-
ment within a particular disease area, relevant psychometric
properties include acceptability, feasibility, reliability, valid-
ity, and responsiveness [6]. The concept of validity refers to
the extent to which an instrument measures what it is
intended to measure, but in this case, all measures of valid-
ity are limited by the fact that there is no gold standard
measure of health utility against which to judge perform-
ance. Brazier and Deverill (1999) identify several criteria
that psychometricians use to measure validity in the ab-
sence of a gold standard measure [6]. ‘Known group valid-
ity’ examines differences between groups which are known
to differ in the concept of interest, e.g health utility. Given
the lack of a gold-standard measure of health utility, in
practice the groups are often defined in terms of clinical
measures such as disease severity. ‘Convergent validity’
refers to the situation where an instrument is highly
correlated with other instruments which measure the same
underlying construct. ‘Discriminant validity’, is where
measures that theoretically should not be related to each
other are observed not to be correlated with each other.
Known-group, convergent and discriminant validity are all
measures of construct validity. Other forms of validity such
as face validity and content validity are concerned with
whether the items of the instrument are appropriate for the
health dimension being measured, in this case the concep-
tual model of health that is accepted to define the “quality
of life” element of QALY calculations. These measures
would need to be assessed in a broader population than
considered here. Responsiveness refers to the ability of an
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time and therefore requires the comparison of longitudinal
data in groups that are known to have changed in the con-
cept of interest. Reliability can be thought of as the stability
of results when using an instrument repeatedly in situations
where the results are not expected to change, such as over
time in the same unchanged population (test-retest reliabil-
ity), or between raters or interviewers (inter-rater reliabil-
ity). The acceptability and feasibility of the EQ-5D is well
established and is not expected to be significantly different
for this population, so the review was limited to measures
of construct validity, reliability and responsiveness.
Results
A total of 67 citations were identified from the biblio-
graphic searches (Figure 1). Of these 38 were ordered as
full-text articles, although nine papers (four reviews and
five economic evaluations) were ordered purely to check
their references for further primary studies. From these
one further paper was identified.
A total of 17 papers were included in the review, the
key features of which are reported in Table 1. Four of
the studies identified were randomised controlled trials
(RCTs), four were cohort studies and nine were cross-
sectional studies. None of the studies were specifically
designed to assess the psychometric properties of the
EQ-5D. One paper reported that its objective was toNumber of potentially relevant records
67
Number of citations screened
67
Number of full text articles assessed
38
Number of studies included in review
17
17 21
Figure 1 Identification of included articles.evaluate the measurement properties of the EQ-5D using
data collected as part of a RCT [7]. Two further studies
aimed to validate another HRQoL instrument [2,8].
The majority of the studies were conducted in a popula-
tion with incontinence. In two studies, a sample of the
general population were asked whether they had a range
of clinical conditions including incontinence [2,9]. These
studies were included as they reported utilities for the sub-
group of patients with incontinence. One study identified
patients from an academic urology unit inpatient database
and examined overactive bladder symptoms including in-
continence [10]. One study was in men with uncompli-
cated urinary tract symptoms associated with benign
prostatic enlargement [11]. A second study was conducted
in outpatients attending a urology department with urin-
ary symptoms (not specifically incontinence) and possible
benign prostatic obstruction [8]. This study also recruited
a general practice sample which was not selected for in-
continence [8]. These studies were included as UI can be
experienced in patients with benign prostatic hyperplasia.
Two papers reported different analyses from the Prospect-
ive Urinary Incontinence Research (PURE) study [12,13].
One paper reporting EQ-5D values from a study [14] had
a second associated paper [15] which was excluded as it
didn’t report EQ-5D values, however the EQ-VAS values
reported in this secondary paper are included in the
results table under the primary paper.Number of citations excluded based on title / 
abstract
29
Number of full text articles excluded –22
Reasons for exclusion:
Protocol only –1
Modeling study – 5 
No relevant data presented –7
Review – 4 
Abstract (insufficient details) – 3 
EQ - 5D utilities not reported –2
Additional articles identified from full text reviews / 
economic evaluations
1
1
Table 1 Characteristics of included studies
Author(s), Year Country Type of incontinence (e.g stress, urge) Treatment (if any) Study type (e.g. cross
sectional, RCT, cohort)
Number of participants
Ternent et al, 2009 [20] UK Stress incontinence No details Cross sectional (self-
selected sample)
105 (of 188 approached)
Ismail et al, 2009 [16] UK Urodynamic stress incontinence Magnetic energy stimulation of
pelvic floor muscles
Cohort 48
Rinne et al, 2008 [22] Finland Stress UI with indications for surgical
treatment
a) Tension-free vaginal tape
(TVT)
RCT 267 (of 273 randomised)
b) TVT obturator (TVT-O)
Haywood et al, 2008 [7] UK Stress and/or urge incontinence in women
referred for physiotherapy from primary or
secondary care.
Physiotherapy Cohort (RCT with data
combined across arms)
174
Monz et al, 2007 [12] 15 European Countries
(UK and Ireland subgroup)
UI of any type in women seeking treatment At discretion of physician Cross-sectional data from
cohort study
9487
Kobelt et al, 2006 [21] France, Germany, Italy,
Sweden, UK
Stress UI NASHA/Dx gel Cohort 82 of 139 enrolled
Dumville et al, 2006 [17] UK Proven stress UI requiring surgery Laparoscopic vs open
colposuspension
RCT 291
Currie et al , 2006 [10] UK Stress and non-stress incontinence in
patients identified from sample which had
been treated by urology department.
None specified Cross-sectional 609 (from 2193 sent survey)
Monz et al, 2005 [13] 15 European countries UI in women seeking treatment None Cross-sectional data from a
cohort study
9487
Manca et al, 2003 [18]
(clinical outcomes from
Ward 2002)
UK Stress incontinence with indication for
surgical management
Tension-free vaginal tape vs
colposuspension
RCT 344
Kobelt, 1997 [14] Sweden Mixed or urge incontinence in patients
who had previously received therapy from
a urotherapist.
None specified Cross-sectional 461 (541 sent questionnaire)
Hawthorne, 2009 [2] Australia General population sample with data on
presence and severity of UI
None Cross-sectional 3015
Tincello et al, 2010 [19] Germany, UK, Sweden &
Ireland
Stress UI, with or without urge symptoms,
in women seeking treatment
36.1% receiving conservative
management at baseline.
18.0% receiving drug therapy
at baseline.
Cross-sectional (baseline
data from cohort study)
3739 of 3762 enrolled
Saarni, 2006 [9] Finland Self-reported UI in general population
sample
None Cross-sectional 8028 of which 13.0% reported UI
Noble et al, 2002 [11] UK Uncomplicated urinary tract symptoms in
men with benign prostatic enlargement
Laser therapy vs Transurethral
prostrate resection vs
conservative management
RCT 340
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Table 1 Characteristics of included studies (Continued)
Mihaylova et al, 2010
[23]
Multicountry Stress UI Duloxetine vs conservative
management vs duloxetine
plus conservative management
vs no treatment
Cohort (non randomised
comparison of treatments)
1510
(Germany, UK & Sweden) 40% had pure stress incontinence with the
rest reporting both stress and urge
incontinence
Donovan et al, 1997 [8] 12 countries Outpatients attending urology department
with symptoms (not specifically
incontinence) and possible benign prostatic
obstruction. GP sample (not selected for
condition)
None Cross-sectional 1271 outpatient sample
423 GP sample (UK)
GP=General Practice NASHA/Dx =non-animal-stabilized hyaluronic acid/dextranome, RCT=randomised controlled trial, UI=urinary incontinence, UK=United Kingdom.
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total number of patients ranged from 48 to 9487. The
mean age across the cohorts with UI varied from 50 to
67. One study reported a higher mean age in the
patients reporting UI than in the general population
sample as a whole (mean age of 64 versus 53) [9], whilst
another reported only the mean age for the general
population sample [2]. Two papers looked exclusively at
males [8,11], four had a mixed population of males and
females [2,9,10,14], and the remainder looked exclusively
at females. Ethnicity was reported in a single study in
which 4% of participants were non-white [10].
The measures reported in each of the included studies
are shown in Table 2 (all abbreviations used to describe
HRQoL instruments are defined below Table 2). In addition
to the EQ-5D, five studies administered the SF36 or some
variant of it [8,10,14,17,18]. One included SF-6D, AQoL,
AQoL-8, and HUI-3 [2] and one reported the 15-D [9].
Several papers reported using the UK valuation set for the
EQ-5D and none reported using an alternative valuation
set, although it was common for this information not to be
reported. Only two studies reported the EQ-VAS [12,14].
The main clinical measures reported were severity, or
grade of incontinence, type of incontinence (stress /
urge / mixed), frequency of leakage episodes and pad
usage or pad tests to determine volume of leakage. Some
studies reported on cough stress tests or cystometry
results. In the benign prostatic hyperplasia populations
maximum flow rate and post void residual volume were
used as measures of treatment effectiveness.
Various symptom scoring and incontinence specific qual-
ity of life tools were also used (KHQ, UISS, I-QOL, IIQ-7,
SSI). Some studies included tools which were designed for
use in patients with overactive bladder rather than incon-
tinence (UDI-6, BFLUTS). Some studies included scales
designed to measure the impact of lower urinary tract
symptoms in men (ICSQoL, IPSS). One study reported a
questionnaire that assesses the likelihood of destrusor in-
stability (DIS) which may be associated with stress incon-
tinence, based on patient history. One study reported
quality of life using a patient generated index (PGI) which
is an individualised health related quality of life measure.
‘Known group’ validity
A summary of those studies that compared the mean
EQ-5D between groups defined in terms of incontinence
severity, frequency or type of incontinence is provided in
Table 3.
Two studies defined groups by the frequency of incon-
tinence episodes [7,19]. In one study, three groups were
defined and the mean EQ-5D consistently reflected
differences between groups and the differences were
statistically significant [19]. In the second study, five
groups were defined [7]. The mean EQ-5D was equal fortwo of the groups and the differences between all the
five groups were not statistically significant. In the same
study, the condition specific measures of SSI and I-QoL
discriminated well between the groups.
Two studies reported ‘known group’ validity by sever-
ity group. In one study the definition of severity was not
well described [2], but in the other [13] a validated se-
verity index was used which was based on combined
scores for frequency and leakage amount. EQ-5D varied
between severity groups as expected in both studies and
had statistically significant differences between severity
groups in one study [2], whilst the other did not report
whether differences were statistically significant [13]. Other
preference based measures (SF-6D, AQoL & AQoL-8), gen-
eric measures (EQ-VAS) and disease specific measures
(I-QoL) were found to perform equally well.
Three studies compared groups defined by incontin-
ence type with two studies distinguishing between stress,
urge and mixed incontinence [13,19] and the other study
grouping patients as general incontinence, stress incon-
tinence or none [10]. It was unclear what differences
were clinically expected between the stress, urge and
mixed groups. However, two studies reported greater
EQ-5D scores for stress incontinence than for urge and
greater utilities for urge than for mixed [13,19]. These
differences were statistically significant in one study and
the other did not report statistical significance. EQ-VAS
had differences across the groups that were consistent
with the differences for EQ-5D except for when severity
was reported as slight. Mean I-QoL score performed simi-
larly to EQ-5D although the differences between the groups
were not consistent for individual I-QoL domains.
In the third study EQ-5D scores were lower for gen-
eral incontinence than for no incontinence as clinically
expected, but statistical significance was not reported [10].
SF-36 performed equally well in distinguishing between UI
type which was categorised as general / stress / none.
Convergent validity
Five studies provided information on the correlation be-
tween EQ-5D and disease specific instruments (KHQ,
PGI, I-QoL, ICS-QoL, SSI) or clinical measures (incon-
tinence grade and number of micturitions / leakages).
Significant correlations in the expected direction were
seen for several but not all of the disease specific
instruments. One study reported a statistically significant
correlation (p<0.01) in the expected direction for both
the I-QoL index and the three I-QoL scale scores [7]. In
the same study, SSI was found not to have a statistically
significant correlation with EQ-5D (p>0.05) [7]. The
correlations between EQ-5D and the individual ICS-QoL
items were all in the expected direction but were not all
statistically significant [8]. One study reported significant
correlations in the expected direction for PGI and KHQ,
Table 2 Measures reported in the included studies
Generic measures Other measures used
Author(s), Year Descriptive system Tariff used Direct valuation Condition-specific HRQoL
measures used
Clinical measures used Qualitative questions
Ternent et al, 2009 [20] EQ-5D Not stated None KHQ None None
PGI
Ismail et al, 2009 [16] EQ-5D Not stated None KHQ 1 hr pad test None
Leakage episodes
Pad usage
Rinne et al, 2008 [22] EQ-5D Not stated None UISS Cough stress test Satisfaction with operation.
DIS 24-hr pad
VAS
IIQ-7
UDI-6
Haywood et al, 2008 [7] EQ-5D States general population
utility weights.
None I-QoL (index and individual
domains)
SSI Subjective treatment benefit
assessed by patient.Incontinence episodes per
week at baseline
Monz et al, 2007 [12] EQ-5D Not stated EQ-VAS I-QOL UI severity (Sandvik Index) Bother (4 point scale)
UI subtype (S/UIQ)
Kobelt et al, 2006 [21] EQ-5D Reference suggests UK
tariff used.
None None Incontinence grade
Median number of episodes
per day
Dumville et al, 2006 [17] EQ-5D UK tariff None None Objective cure* (negative
1 hr pad test)
Subjective cure* (perfectly
happy / pleased) to spend
rest of life with current
urinary symptoms
SF-36
*(reported in related clinical
paper)
Currie et al, 2006 [10] EQ-5D Not stated None None None None
SF-36
Monz et al, 2005 [13] EQ-5D Not stated None I-QOL Sandvik index (severity based
on frequency and leakage
amount)
Bothersomeness and
limitations of daily activities
Manca et al, 2003 [18] EQ-5D UK tariff Objective cure (based on
negative pad test and
negative cystometry)
SF-36
Subjective cure (based on
BFLUTS)
Kobelt, 1997 [14] EQ-5D UK tariff. EQ-VAS [15] Frequency of micturitions
and involuntary urine loss
(combined measure)
SF-36
Hawthorn, 2009 [2] EQ-5D EQ-5D: UK tariff
SF-6D
AQoL SF-6D: Not stated
AQoL-8 (derived from AQoL &
AQoL) AQoL-8: community TTO
HUI-3 (deciles)
Tincello et al, 2010 [19] EQ-5D UK tariff None None Episodes per week None
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Table 2 Measures reported in the included studies (Continued)
Saarni, 2006 [9] EQ-5D EQ-5D: UK tariff None None None
15-D 15-D Finnish valuation set
Noble et al, 2002 [11] EQ-5D Not stated None I-PSS which includes a quality
of life score.
Maximum flow rate
Post void residual urine
Number of successful
procedures (based on I-PSS
and maximum urinary flow)
Mihaylova et al, 2010 [23] EQ-5D UK tariff Number of leaks during
7 days
Donovan et al, 1997 [8] EQ-5D (UK, Denmark and
Netherland only, N=359)
Not reported ICSQol (ICSmale)
SF-36 (UK only, N=205)
AQoL=Assessment of Quality of Life, BFLUTS=Bristol Female Lower Urinary Tract Symptoms Questionnaire, DIS= Detrusor instability scores, EQ-VAS=Visual analogue scale which accompanies the EQ-5D descriptive
system, HUI-3=Health Utilities Index Mark 3, ICSQol=International Continence Society – Benign Prostatic Hyperplasia study Quality of Life Instrument, IIQ-7=Incontinence Impact Questionnaire-short form, I-PSS =
International Prostate Symptom Score, I-QOL=Incontinence specific Quality of life Questionnaire, KHQ=King’s Health Questionnaire, PGI = Patient Generated Index, SF-36=Medical outcomes study 36-Item Short-Form
Health Survey , SF-6D= Classification for describing health derived from a selection of SF-36 items, SSI=Symptom Severity Index, S/UIQ=Stress and Urge Incontinence Questionnaire, UDI-6=Urogenital Distress
Inventory-short form, UI=Urinary incontinence, UISS=Urinary Incontinence Severity Score, VAS=Visual Analogue Scale, 15-D=Fifteen dimension generic instrument.
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Table 3 Results of ‘known group’ comparisons
Author(s), Year Groups defined as Instrument Direction of change consistent across groups
and consistent with clinical expectation?
Difference between groups
statistically significant?
Haywood et al, 2008 [7] Number of episodes at
baseline:
EQ-5D Yes‡ No at p=0.01
Not at all
SSI Yes Yes, p<0.01
A few days
I-QoL
index
Yes Yes, p<0.01
Half the week
I-QoL
domains
Mixed† Yes, p<0.01Most days
Every day
Tincello et al, 2010 [19] Episode frequency:
<=7 per week EQ-5D Yes Yes, p<0.0001
7 to 13 per week
>=14 per week
Monz et al, 2005 [13] Severity (reported for
each subtype)
Slight EQ-5D Yes Not reported
Moderate EQ-VAS Yes Not reported
Severe Mean
I-QoL
Yes Not reported
Very severe I-QoL
domains
Yes Not reported
Hawthorne, 2009 [2] Continence status:
a) None EQ-5D Yes Yes, p<0.0001
b) Slight/mild SF-6D Yes Yes, p<0.0001
c) Moderate AQoL Yes Yes, p<0.0001
d) Severe AQoL-8 Yes Yes, p<0.0001
Currie et al, 2006 [10] Type of incontinence:
General EQ-5D Stress<general<none* Not reported
Stress SF-36 As for EQ-5D As for EQ-5D
None
Monz et al, 2005 [13] Subtype (reported for
each severity category):
EQ-5D Stress>urge>mixed* Not reported
EQ-VAS As for EQ-5D (except when severity slight) Not reportedStress
Mean
I-QoL
As for EQ-5D Not reported
Urge I-QoL
domains
No consistent pattern across all domains Not reported
Mixed
Tincello et al, 2010 [19] UI subtype:
Mixed EQ-5D Stress>urge>mixed* Yes, p<0.0001
Pure stress
Pure urge
†Yes for 2/3 domains, ‡Same mean for two least severe domains, *Unclear which type of incontinence is expected to have lower utility. VAS=visual analogue
scale, I-QOL=Incontinence specific Quality of life Questionnaire, SSI= symptom severity index, SF-36=Medical outcomes study 36-Item Short-Form Health Survey,
SF-6D= Classification for describing health derived from a selection of SF-36 items, AQoL= Assessment of Quality of Life.
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were found with incontinence grade (p<0.05) [21] and the
number of micturitions and leakages (p<0.001) [14].
Two studies used regression techniques to assess the
impact of clinical measures on EQ-5D scores. Severity,
subtype of incontinence (e.g stress / urge) and number
of episodes were found to be significant predictors
[12,19]. Two studies used multivariate regression to
examine whether presence of incontinence was a signifi-
cant predictor of utility. The first found that presence of
incontinence was a significant predictor of EQ-5D in
urology patients and was also a significant predictor of
SF-36 scores [10]. The second study found that incontin-
ence was a significant predictor of both EQ-5D and 15D
in a general population sample and the size of utility loss
was similar between these two instruments [9].
Responsiveness
Results from studies that provide details on the responsive-
ness of EQ-5D in incontinence are reported in Table 4. Five
studies reported changes in EQ-5D from baseline and
compared this to changes in disease specific or clinical
measures [11,16,18,21,22]. Generally there was agreement
between changes in EQ-5D and changes in clinical or
disease specific measures with four studies reporting
improvements in both [11,18,21,22] although two studies
did not report whether the EQ-5D changes were statistically
significant [11,18]. In one study there was no significant
change in either EQ-5D or clinical outcomes [16].
One study reported changes from baseline for patients
whose continence-specific health improved [7]. In this sub-
group significant changes from baseline were seen in SSI
and I-QoL, but not EQ-5D at six weeks. However, by five
months when greater changes from baseline were seen for
SSI and I-QoL, the EQ-5D changes were also found to be
larger and statistically significant. This study also reported
mean scores for responders and non-responders with re-
sponse being based on patient perceived benefit. There
were significant differences between responders and non-
responders in two of the I-QoL domains at six weeks, but
differences in SSI, I-QoL index and EQ-5D were non-
significant. However, by five months EQ-5D differences
were found to be significant although only one I-QoL do-
main remained significantly different between responders
and non-responders.
Five studies reported whether the difference between
treatment groups was significant for both EQ-5D and
for other measures (clinical, disease specific measures
and generic HRQoL) [11,17,18,22,23]. In three studies
there were no statistically significant differences in EQ-5D
between treatment groups and this agreed with the other
trial outcomes [17,18,22]. In one of these studies some sig-
nificant differences were found in some domains of the
SF-36 but not in the other clinical outcomes (objective andsubjective cure rates) [18]. One study found differences in
EQ-5D scores between the treatment arms that were con-
sistent with the clinical outcomes, but the statistical signifi-
cance of the EQ-5D differences was not reported [11]. In
another study six comparisons were made between the four
treatment options (three active and one no treatment) [23].
For the three comparisons of active treatment against no
treatment, all three active treatments were more clinically
effective than no treatment but only two had significantly
better EQ-5D scores. For the three comparisons between
the active treatment arms, no significant differences were
seen in the clinical effectiveness, but there were significant
differences in the EQ-5D scores for two comparisons.
One study reported standardised response means for
different instruments [7]. The standardised response
means were lower for EQ-5D than for disease specific
measures (SSI and I-QoL).
Key findings on re-test reliability
One study reported the intraclass correlation coefficient
(ICC) for patients reporting no benefits from treatment
during a clinical trial (data from both trial arms were
combined) [7]. The test-retest correlation for EQ-5D
was 0.83 (n=50).
Discussion
The EQ-5D appears to be a reasonable instrument to use
in this population when considering the psychometric
measures of construct validity, responsiveness and reliabil-
ity. In most situations EQ-5D performs well when assessed
by ‘known group’ validity or responsiveness. In most of the
responsiveness tests performed, EQ-5D was consistent with
clinical or disease specific outcome measures, including in
achieving statistical significance. However, there were
situations where statistical significance was not achieved.
Psychometric measures such as validity, reliability and
responsiveness are often used to support claims that a
HRQoL instrument is adequate or inadequate in a par-
ticular population. These measures rely on making
comparisons between the scores achieved by the HRQoL
instrument and other instruments or clinical measures
which are expected to be related. However, when the in-
strument in question intends to measure health utility,
as EQ-5D does, these comparisons are not tests. They
can highlight differences between EQ-5D and other
instruments such as other generic instruments, disease
specific outcomes or clinical measures, but since there is
no gold standard it cannot be established conclusively
which measure is “right”. Intuition and judgement are
required to draw any stronger conclusions. Another
issue for consideration when interpreting the results is
that the populations of the included studies are somewhat
diverse with some studies recruiting patients specifically
with symptoms of UI and other studies recruiting patients
Table 4 EQ-5D responsiveness results
Author(s),
Year
Comparison Change in clinical measure(s)
or other preference based
utility
Change in EQ-5D Agreement with
direction?
Agreement with
statistical
significance?
Ismail et al, 2009
[16]
Change over time No significant change on any
measure (KHQ,1 hr pad test,
pad use, leakage episodes)
No significant change NA Yes
Rinnie et al, 2008
[22]
Change over time 24 hr pad test significantly
improved in both arms
Significant improvement in
both arms
Yes Yes
All condition specific measures
(UISS, DIS, VAS, IIQ-7, UDI-6)
significantly improved in both
treatment groups
EQ-VAS significantly improved
in both treatment groups
Difference between
treatment arms
No significant difference in
objective cure, leakage,
complication rate, UISS, DIS,
VAS, IIQ-7, UDI-6.
No significant difference in
EQ-5D
Agreement with
some clinical
outcomes and not
others.
Yes
Haywood et al
2008 [7]
Comparison of
means for
responders and non-
responders
6 week data: 6 week data: 6 week data: 6 week data:
SSI and I-QoL index had
difference in expected
direction but not statistically
significant (at p=0.01). Two of
the I-QoL domains had
significant difference.
EQ-5D had difference in
expected direction but not
statistically significant (at
p=0.01).
Yes Not consistent
with all
5 mth data: 5 mth data: 5 mth data: 5 mth data:
As for 6 weeks except only one
of the I-QoL domains had
significant (p<0.01) difference.
EQ-5D had difference in
expected direction and
statistically significant
(p=0.01).
Yes Not consistent
with all.
Mean change scores
for patients
reporting
improvement
6 week data: 6 week data: 6 week data: 6 week data:
Expected direction and
significant (at p=0.05) for SSI, I-
QoL index, I-QoL domains
Expected direction but
p>0.05
Yes No
5 mth data: 5 mth data: 5 mth data: 5 mth data:
As for 6 weeks but larger
changes.
Expected direction and
p<0.05.
Yes Yes
MSRM for patients
reporting
improvement
6 week data: 6 week data: 6 week data: 6 week data:
SSI, 0.70 0.07 Yes No
I-QoL index, 1.01
I-Qol domains, 0.40 to 0.94
5 mth data: 5 mth data: 5 mth data: 5 mth data:
SSI, 0.67 0.26 Yes Yes
I-QoL index, 1.17
I-Qol domains, 0.80 to 1.25
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Table 4 EQ-5D responsiveness results (Continued)
Kobelt et al, 2006
[21]
Median
incontinence
episodes per day for
clinical outcome but
change from
baseline for EQ-5D
All patients: All patients: All patients All patients
3.0 at baseline, 0.7 at 3mths
and 0.9 at 12 mths (p<0.0001
and p<0.001 for differences)
3 mths: 0.048 (p<0.001)
6 mths: 0.014 (not significant)
3 mths: Yes 3 mths: Yes
12 mths: “gain remained
evident”
12 mths: Yes 12 mths: Yes
Patients with utility<1 at
baseline:
Patients with utility
<1 at baseline:
Patients with
utility <1 at
baseline:
3 mths: 0.099 (p<0.01)
6 mths: 0.065 (p<0.001)
12 mths: “significant
improvements”
As for all patients As for all
patients
Dumville et al,
2006 [17]
Difference between
treatment arms:
Objective and subjective cure
rates and SF-36 scores showed
no significant difference
QALY gain based on EQ-5D
utility scores showed no
significant difference (CrI
crossed zero)
No change in either
clinical, generic
HRQoL or utility
Yes
Manca et al, 2003
[18]
Differences from
baseline to 6mths
Pad weight decreased
significantly for both groups.
Utility increased in both arms
(significance not reported)
Yes Not reported
Significant reduction in leakage
episodes in both groups
(P<0.0001)
Significant reduction in 21/30
symptoms (BFLUTS) in both
groups (P<0.0001)
Differences between
trial arms:
No significant difference in
objective or subjective cure
rate between trial arms
QALY difference between
arms based on EQ-5D scores
non significant at p=0.05
Agreement with
clinical outcomes but
didn’t detect
differences between
arms in some SF-36
domains
Yes for clinical
outcomes, no for
some SF-36
domains
SF-36 scores had significantly
smaller improvement/ greater
decline lower for
colposuspension group vs TVT
in four domains at 6 weeks
and four domains (three same
and one different) at 6 mths.
Noble et al, 2002
[11]
Change from
baseline:
Improvements in I-PSS,
maximum urine flow, and
residual volume were
significant (p=0.05) for laser
and resection but not
conservative.
Means increased for laser and
resection but not
conservative (p values not
reported)
Yes Not reported
Improvements in I-PSS QoL
were significant for all three
interventions.
Differences between
trial arms:
Resection vs conservative and
laser vs conservative showed
significant difference in all four
outcomes.
Gains were greater for
resection than laser therapy
(p values not reported)
Yes Not reported
Laser vs resection showed
significant difference in only
one outcome which was in
favour of resection (maximum
flow)
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Table 4 EQ-5D responsiveness results (Continued)
Mihaylova et al,
2010 [23]
Comparison
between active
treatment arms and
no treatment:
Number of leaks avoided per
week was significantly (p<0.01)
better for Duloxetine alone,
conservative alone and
duloxetine plus conservative
(all relative to no treatment).
QALY gains based on EQ-5D
utility were significant for
Duloxetine alone (p<0.01)
and duloxetine plus
conservative treatment
(p<0.05) but conservative
alone was not significant and
was negative (all compared
to no treatment)
Yes for two of three
comparisons against
no treatment
Yes for two of
three
comparisons
against no
treatment
Comparison
between the three
active treatment
arms:
No significant reduction in
number of leaks for 3
comparisons between active
treatment arms.
Significant (p<0.05) QALY
gains for 2 of 3 comparisons
between active treatment
arms.
Yes for 2 of 3
comparisons between
active treatment arms.
No for 2 of 3
comparisons
between active
treatment arms.
MSRM=modified standardised response mean.
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overactive bladder and benign prostatic enlargement.
Limitations to the studies included in the review can
only further dilute the conclusions that may be drawn.
In particular, none of the studies reported here were
specifically designed to test the appropriateness of the
EQ-5D, they simply provided data which was potentially
relevant. Where studies are not explicitly powered to
detect a difference in EQ-5D scores, a lack a statistical
significance in a particular comparison may be related to
the size of the sample rather than a reflection on the
appropriateness of the EQ-5D. Further more, sometimes
not all of the data relevant to assessing a particular
psychometric property were provided. For example, three
of the studies providing data on responsiveness were RCTs
reporting changes from baseline for the EQ-5D and other
clinical measures, but two did not report whether the
EQ-5D changes were statistically significant.
Where known groups are defined in terms of some
clinical measure, the distinctions between groups may
reasonably not translate to differences in health utilities.
For example, Haywood et al. found that EQ-5D was not
able to fully discriminate between 5 groups [7]. The groups
were defined in terms of the number of episodes as “not at
all”, “a few days”, “half the week”, “most days” and “every
day”. The differences between the groups are therefore
relatively small, not necessarily mutually exclusive, and it is
questionable whether there would be significant differences
in the preferences of patients in some of the groups.
Furthermore, the reporting of the extent to which an in-
strument is consistent with groups defined in another way
needs to consider how many groups are being considered.
Often there are multiple groups being compared and the
instrument may provide consistent results across many of
them. P-values typically relate to the null hypothesis that
the mean value is equal in all the subgroups under consid-
eration. This itself may be ambiguous because it does not
consider how many of the individual pairs of comparisons
are statistically significant. It also does not discriminatebetween situations where the observations are all consist-
ent i.e. statistical significance provides support for the val-
idity of the instrument, versus those where one or more
observations appear to be inconsistent i.e. statistical sig-
nificance may or may not provide support for the validity
of the instrument. Given the multiple issues identified
regarding tests of statistical significance in this context, we
recommend that caution should be exercised when
interpreting any measures of a psychometric property
which rely on tests of statistical significance.
The EuroQol Group have approved the development of
“bolt-ons/dimension extensions” [24]. These instruments
will permit the addition of extra dimensions to the standard
EQ-5D instrument in order to directly capture other issues
of importance to patients. How precisely these bolt-ons are
approached remains to be seen, but this may be a route to
addressing symptoms such as incontinence which are not
captured directly by any of the current dimensions. This re-
view has not identified any strong evidence to suggest that
the impact of incontinence is not adequately captured in-
directly through the existing dimensions, although it did
not examine content validity directly. A review by Lin et al
identified several candidate areas for bolt-ons by comparing
the content of disease specific preference based measures
to that of the EQ-5D across a wide variety of disease areas
[25]. Despite including one paper in patients with urinary
incontinence and another in patients with overactive blad-
der, incontinence was not identified by Lin et al. as a poten-
tial candidate for bolt-ons to the EQ-5D. One of the key
advantages of the EQ-5D, which may be threatened by the
addition of bolt-on dimensions, is that it provides a generic
measure of HRQoL that allows decision makers to apply a
consistent approach to economic evaluation across multiple
disease areas.
Conclusions
This review provides a narrative summary of the evidence
available on the appropriateness of the EQ-5D instrument
in assessing the health impact of UI. The EQ-5D was
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ity, responsiveness and reliability, although no definitive
conclusion can be made on its appropriateness based on
these measures alone.
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